Astrazeneca (AZN) closed at $79.76 in the latest trading session, marking a +1.49% move from the prior day. This change outpaced the S&P 500's 1.39% loss on the day. On the other hand, the Dow registered a gain of 0.6%, and the technology-centric Nasdaq decreased by 2.77%. The pharmaceutical's shares have seen an increase of 0.22% over the last month, not keeping up with the Medical sector's gain of 1.98% and the S&P 500's gain of 4.43%. Analysts and investors alike will be keeping a close eye on the performance of Astrazeneca in its upcoming earnings disclosure. The company's earnings report is set to go public on July 25, 2024. The company is predicted to post an EPS of $0.96, indicating a 11.11% decline compared to the equivalent quarter last year. Our most recent consensus estimate is calling for quarterly revenue of $12.57 billion, up 10.14% from the year-ago period. For the annual period, the Zacks Consensus Estimates anticipate earnings of $4.05 per share and a revenue of $51.95 billion, signifying shifts of +11.57% and +13.41%, respectively, from the last year. It's also important for investors to be aware of any recent modifications to analyst estimates for Astrazeneca. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook. Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system. The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, there's been a 0.33% rise in the Zacks Consensus EPS estimate. Astrazeneca presently features a Zacks Rank of #3 (Hold). Digging into valuation, Astrazeneca currently has a Forward P/E ratio of 19.41. This indicates a premium in contrast to its industry's Forward P/E of 14.98. It is also worth noting that AZN currently has a PEG ratio of 1.41. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. As of the close of trade yesterday, the Large Cap Pharmaceuticals industry held an average PEG ratio of 1.88. The Large Cap Pharmaceuticals industry is part of the Medical sector. With its current Zacks Industry Rank of 163, this industry ranks in the bottom 36% of all industries, numbering over 250. The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. To follow AZN in the coming trading sessions, be sure to utilize Zacks.com. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AstraZeneca PLC (AZN):Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
Astrazeneca (AZN) Rises As Market Takes a Dip: Key Facts
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...